ÜBER DIESE EPISODE
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting.
He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries.
Dr Beer describes how unregulated access and off-label use of precision medicine is damaging precision medicine in American clinics, compared to hurdles in data access and funding facing European researchers.
He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries.
Dr Beer describes how unregulated access and off-label use of precision medicine is damaging precision medicine in American clinics, compared to hurdles in data access and funding facing European researchers.
Englisch
Vereinigte Staaten
TRANSKRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
VERGANGENE FOLGEN SUCHEN
Vorhandene Folgen von IBCD 2016 durchsuchen.
WEITERE EPISODEN IN DIESEM PODCAST
Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials.
He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for personali…
Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment.
She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays.
He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes.
He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of…
Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von ecancer.org, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.
BEARBEITEN
Vielen Dank, dass Sie uns helfen, die Podcast-Datenbank auf dem neuesten Stand zu halten.
